Teleflex to acquire Biotronik’s vascular intervention business for $791M, split into 2 separate entities
Teleflex Inc., the Pennsylvania-based medtech company, has agreed to acquire a majority of Biotronik’s vascular intervention business for approximately $791 million in cash. The transaction is expected to be finalized by the end of third quarter of 2025.
The acquisition comes at a time when Teleflex is investing heavily in the expansion of its interventional cardiology and peripheral vascular markets. The company will gain a variety of devices, including drug-coated balloons, drug-eluting stents, balloon catheters, and balloon and self-expanding bare metal stents.
“We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing interventional business and establish our global footprint in the fast-growing peripheral intervention market,” Liam Kelly, Teleflex’s chairman, president and CEO, said in a statement. “In particular, the acquired coronary products will be highly complementary to our well-established complex percutaneous coronary intervention platform and expand and enhance the legacy interventional salesforce and offerings by combining existing Teleflex access products with the vascular intervention therapeutic devices. The acquired business is rooted in robust research and development, clinical expertise, and global manufacturing capabilities, which we believe will further bolster Teleflex’s innovation pipeline, and position the company to participate in the emerging potential for resorbable scaffold technologies.”
Teleflex splits into two publicly traded companies
Teleflex also announced its plan to split into two separate entities: a new, independent company made up of its urology, acute care and OEM businesses and a second company made up of its vascular access, interventional and surgical businesses. The newly acquired assets from Biotronik will be a key piece of the latter business.
“This transaction is designed to optimize the positioning of both companies in order to better meet the needs of patients and customers and maximize value for shareholders,” Kelly said in a separate statement.
Once the separation is finalized—the process may take more than a full calendar year—Kelly will remain in his position and oversee the vascular access, interventional and surgical businesses. New leaders will soon be identified for the urology, acute care and OEM businesses.
Biotronik shifting its focus
For Biotronik, his move represents a key part of its new strategy to “strengthen its leadership in active implantable devices and digital healthcare.”
“We are incredibly proud of the transformative contributions our Vascular Intervention division has made to interventional therapies and patient care worldwide,” Dr. Alexander Uhl, CEO of Biotronik Group, said in a company statement. “As healthcare continues to rapidly evolve, our focus is firmly on advancing AI-driven technologies that meet the needs of both patients and clinicians in the years to come. This strategic shift empowers us to amplify our investments in emerging technologies across cardiac rhythm management, patient monitoring, heart failure, and neuromodulation therapies.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.